I-09 Yucheng Sheng Item response theory modelling of motor scores to investigate feasibility of reducing proof-of-concept trial for Parkinson’s disease Wednesday 10:10-11:40 |
I-11 Alena Simalatsar Personalised delivery rate computation for intravenously administered anesthetic using Kalman filter Wednesday 10:10-11:40 |
I-44 Michiel Van Esdonk Population pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjects Wednesday 10:10-11:40 |
I-78 Xiao Zhu Application of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptor Wednesday 10:10-11:40 |
II-27 Anais Glatard Population pharmacokinetic model of amisulpride for individual dosing in psychiatric patients Wednesday 15:50-17:20 |
II-61 Siv Jonsson Sample size for detection of drug effect using item level and total score models for Unified Parkinson’s Disease Rating Scale data Wednesday 15:50-17:20 |
III-04 Jae Eun Ahn Pharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers Thursday 09:55-11:30 |
III-23 Agnieszka Bienert Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery. Thursday 09:55-11:30 |
III-34 Thierry Buclin Closed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study Thursday 09:55-11:30 |
III-54 Valerie Cosson Population PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease Thursday 09:55-11:30 |
III-57 Ailing Cui Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke Thursday 09:55-11:30 |
III-62 Olivier David A PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor. Thursday 09:55-11:30 |
III-69 Oleg Demin Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology Thursday 09:55-11:30 |
IV-01 Brigitte Lacroix A quantitative framework integrating exposure, efficacy, receptor occupancy and tolerability to propose evidence-based dose regimens for padsevonil Thursday 15:10-16:40 |
IV-06 Woo Yul Lee A population pharmacodynamic model of combination antidepressant therapy in depression Thursday 15:10-16:40 |
IV-09 Giulia Lestini Two-step modelling approach of time to event and cognitive decline to inform Alzheimer’s disease prevention trials Thursday 15:10-16:40 |
IV-10 Leticia Arrington A Model Based Meta-Analysis (MBMA) to support development of medicines for treatment of DPN, PHN and Fibromyalgia. Thursday 15:10-16:40 |
IV-25 Tomomi Matsuura Clinical validation of a quantitative systems pharmacology (QSP) model for nerve-growth-factor (NGF) therapies Thursday 15:10-16:40 |
IV-33 Denise Morris Population Pharmacokinetic Modeling of Fremanezumab in Support of Phase 3 Development for Patients with Migraine Thursday 15:10-16:40 |
IV-59 Etienne Pigeolet Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment. Thursday 15:10-16:40 |